Literature DB >> 25196915

Evidence for substrate binding-induced zwitterion formation in the catalytic Cys-His dyad of the SARS-CoV main protease.

Alexander Paasche1, Andreas Zipper, Simon Schäfer, John Ziebuhr, Tanja Schirmeister, Bernd Engels.   

Abstract

The coronavirus main protease (M(pro)) represents an attractive drug target for antiviral therapy of coronavirus (CoV) infections, including severe acute respiratory syndrome (SARS). The SARS-CoV M(pro) and related CoV proteases have several distinct features, such as an uncharged Cys-His catalytic dyad embedded in a chymotrypsin-like protease fold, that clearly separate these enzymes from archetypical cysteine proteases. To further characterize the catalytic system of CoV main proteases and to obtain information about improved inhibitors, we performed comprehensive simulations of the proton-transfer reactions in the SARS-CoV M(pro) active site that lead to the Cys(-)/His(+) zwitterionic state required for efficient proteolytic activity. Our simulations, comprising the free enzyme as well as substrate-enzyme and inhibitor-enzyme complexes, lead us to predict that zwitterion formation is fostered by substrate binding but not inhibitor binding. This indicates that M(pro) employs a substrate-induced catalytic mechanism that further enhances its substrate specificity. Our computational data are in line with available experimental results, such as X-ray geometries, measured pKa values, mutagenesis experiments, and the measured differences between the kinetic parameters of substrates and inhibitors. The data also provide an atomistic picture of the formerly postulated electrostatic trigger involved in SARS-CoV M(pro) activity. Finally, they provide information on how a specific microenvironment may finely tune the activity of M(pro) toward specific viral protein substrates, which is known to be required for efficient viral replication. Our simulations also indicate that the low inhibition potencies of known covalently interacting inhibitors may, at least in part, be attributed to insufficient fostering of the proton-transfer reaction. These findings suggest ways to achieve improved inhibitors.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25196915     DOI: 10.1021/bi400604t

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  25 in total

Review 1.  Paxlovid: Mechanism of Action, Synthesis, and In Silico Study.

Authors:  Mahrokh Marzi; Mohammad Kazem Vakil; Maryam Bahmanyar; Elham Zarenezhad
Journal:  Biomed Res Int       Date:  2022-07-07       Impact factor: 3.246

2.  Interactive Molecular Dynamics in Virtual Reality Is an Effective Tool for Flexible Substrate and Inhibitor Docking to the SARS-CoV-2 Main Protease.

Authors:  Helen M Deeks; Rebecca K Walters; Jonathan Barnoud; David R Glowacki; Adrian J Mulholland
Journal:  J Chem Inf Model       Date:  2020-11-11       Impact factor: 4.956

3.  Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1.3 Billion Compounds.

Authors:  Anh-Tien Ton; Francesco Gentile; Michael Hsing; Fuqiang Ban; Artem Cherkasov
Journal:  Mol Inform       Date:  2020-03-23       Impact factor: 4.050

Review 4.  Genomics insights of SARS-CoV-2 (COVID-19) into target-based drug discovery.

Authors:  P Chellapandi; S Saranya
Journal:  Med Chem Res       Date:  2020-07-31       Impact factor: 2.351

Review 5.  Recent progress in the discovery of inhibitors targeting coronavirus proteases.

Authors:  Haofeng Wang; Song Xue; Haitao Yang; Cheng Chen
Journal:  Virol Sin       Date:  2016-02-19       Impact factor: 4.327

6.  The crystal structure of main protease from mouse hepatitis virus A59 in complex with an inhibitor.

Authors:  Wen Cui; Shanshan Cui; Cheng Chen; Xia Chen; Zefang Wang; Haitao Yang; Lei Zhang
Journal:  Biochem Biophys Res Commun       Date:  2019-03-02       Impact factor: 3.575

7.  Mechanism of inhibition of SARS-CoV-2 Mpro by N3 peptidyl Michael acceptor explained by QM/MM simulations and design of new derivatives with tunable chemical reactivity.

Authors:  Kemel Arafet; Natalia Serrano-Aparicio; Alessio Lodola; Adrian J Mulholland; Florenci V González; Katarzyna Świderek; Vicent Moliner
Journal:  Chem Sci       Date:  2020-11-27       Impact factor: 9.825

8.  Asymmetric Disulfanylbenzamides as Irreversible and Selective Inhibitors of Staphylococcus aureus Sortase A.

Authors:  Fabian Barthels; Gabriella Marincola; Tessa Marciniak; Matthias Konhäuser; Stefan Hammerschmidt; Jan Bierlmeier; Ute Distler; Peter R Wich; Stefan Tenzer; Dirk Schwarzer; Wilma Ziebuhr; Tanja Schirmeister
Journal:  ChemMedChem       Date:  2020-03-25       Impact factor: 3.466

9.  Computational Studies of SARS-CoV-2 3CLpro: Insights from MD Simulations.

Authors:  Alessandro Grottesi; Neva Bešker; Andrew Emerson; Candida Manelfi; Andrea R Beccari; Francesco Frigerio; Erik Lindahl; Carmen Cerchia; Carmine Talarico
Journal:  Int J Mol Sci       Date:  2020-07-28       Impact factor: 5.923

10.  Structural basis for the development of SARS 3CL protease inhibitors from a peptide mimic to an aza-decaline scaffold.

Authors:  Kenta Teruya; Yasunao Hattori; Yasuhiro Shimamoto; Kazuya Kobayashi; Akira Sanjoh; Atsushi Nakagawa; Eiki Yamashita; Kenichi Akaji
Journal:  Biopolymers       Date:  2016-11-04       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.